Trials in Virginia.
34 APOE4-relevant Alzheimer’s trials run in Virginia — 16 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, genotype not trackedNCT03113461MCI: CPAP Treatment of OSA (Memories2)
This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild…
- Genotype irrelevant, community-specific trialNCT03909347PLAN: Dementia Literacy Education and Navigation for Korean Elders With Probable Dementia and Their Caregivers
This trial is testing a community health worker program called PLAN, designed to help Korean American elders who may have undiagnosed dementia get connected to…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Caregiver study, genotype not relevantNCT04863859Persons With Dementia and Their Extended Family Caregivers
This study is not a clinical drug or device trial. Researchers are interviewing extended family caregivers of people living with dementia to learn how they…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Screening registry, genotype not targetedNCT05364307Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
This is not a treatment trial. APHELEIA is a prescreening registry designed to find and evaluate people who might qualify for future Alzheimer's therapeutic…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- General aging study, genotype not consideredNCT05574634The Role of the Locus Coeruleus in Age-related Distractibility
This trial is studying a small brain region called the locus coeruleus and how its connections to attention networks may explain why older adults get more…
- Observational only, genotype not consideredNCT05601856Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
This study is not a treatment trial. Researchers are comparing gut bacteria and blood markers in three groups: people with Alzheimer's dementia, their spouses,…
- ARIA-focused — carriers often restrictedNCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, not 4-specificNCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…
- Open to carriers, not 4-specificNCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…
- Open to carriers, not 4-specificNCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…
- Open to carriers, not 4-specificNCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…
- Anti-amyloid combo — carriers face higher ARIA riskNCT06602258A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker…
- Open to carriers, not 4-specificNCT06718686Rifaximin SSD in Dementia Trial
This trial is testing a new low-dose formulation of rifaximin, an antibiotic that stays in the gut rather than entering the bloodstream, to see whether it can…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Extension only, ARIA risk relevant to carriersNCT07105709Open-label Extension Study in Participants With Early Alzheimer's Disease
This is an open-label extension study, meaning all participants receive the drug GSK4527226 — no placebo. It is only open to people who already completed the…
- Carriers tracked, ARIA risk significantNCT07169578A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug, against a placebo in people with early Alzheimer's disease — specifically those at the MCI or…
- Anti-amyloid drug — carriers verify eligibilityNCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive…
- Gateway study, genotype not specifiedNCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
- Open to carriers, genotype not studiedNCT07180147Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
ALOHA is an observational study tracking brain and body health in adults 50 and older in the Washington D.C. area over five years. Participants get a full…
- No Alzheimer's or APOE4 relevanceNCT07332377mHealth Intervention for Pain Self Management
This trial is testing a smartphone app designed to help cancer survivors manage pain and other symptoms after treatment ends. Researchers want to see if the…
- Caregiver study, genotype irrelevantNCT07377331Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer
This trial tests an online teaching method called Structured Retrieval Practice to help family caregivers better understand and manage the behavioral and…
- Caregiver study, genotype irrelevantNCT07413406Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers
This trial tests two ways of teaching dementia caregivers practical skills. One group uses structured retrieval practice, a method where you repeatedly recall…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.